Literature DB >> 9578008

Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings.

M M Stecker1, T H Kramer, E C Raps, R O'Meeghan, E Dulaney, D J Skaar.   

Abstract

PURPOSE: We compared propofol with high-dose barbiturates in the treatment of refractory status epilepticus (RSE) and propose a protocol for the administration of propofol in RSE in adults, correlating propofol's effect with plasma levels.
METHODS: Sixteen patients with RSE were included; 8 were treated primarily with high-dose barbiturates and 8 were treated primarily with propofol.
RESULTS: Both groups of patients had multiple medical problems and a subsequent high mortality. A smaller but not statistically significant fraction of patients had their seizures controlled with propofol (63%) than with high-dose barbiturate therapy (82%). The time from initiation of high-dose barbiturate therapy to attainment of control of RSE was longer (123 min) than the time to attainment of seizure control in the group receiving propofol (2.6 min, p = 0.002). Plasma concentrations of propofol associated with control of SE were 14 microM +/- 4 (2.5 microg/ml). Recurrent seizures were common when propofol infusions were suddenly discontinued but not when the infusions were gradually tapered.
CONCLUSIONS: If used appropriately, propofol infusions can effectively and quickly terminate many but not all episodes of RSE. Propofol is a promising agent for use in treating RSE, but more studies are required to determine its true value in comparison with other agents.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578008     DOI: 10.1111/j.1528-1157.1998.tb01269.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  33 in total

1.  Convulsive Status Epilepticus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-09       Impact factor: 3.598

2.  The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: a survey among epileptologists and critical care neurologists.

Authors:  M Holtkamp; F Masuhr; L Harms; K M Einhäupl; H Meierkord; K Buchheim
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

3.  Treatment of refractory status epilepticus in childhood.

Authors:  John M Schreiber; William D Gaillard
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

4.  Recent and future advances in the treatment of status epilepticus.

Authors:  Felix Rosenow; Susanne Knake
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

5.  Use of propofol to control refractory involuntary movements.

Authors:  David V Lardizabal; Vivek Sabharwal; Ali Jahan; Samay Jain; Christopher Snyder; Marc J Popovich; Michael DeGeorgia
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

6.  A randomized trial for the treatment of refractory status epilepticus.

Authors:  Andrea O Rossetti; Tracey A Milligan; Serge Vulliémoz; Costas Michaelides; Manuel Bertschi; Jong Woo Lee
Journal:  Neurocrit Care       Date:  2011-02       Impact factor: 3.210

7.  Status epilepticus.

Authors:  D H Lowenstein
Journal:  West J Med       Date:  1998-04

Review 8.  Antiseizure medications in critical care: an update.

Authors:  Baxter Allen; Paul M Vespa
Journal:  Curr Opin Crit Care       Date:  2019-04       Impact factor: 3.687

9.  Status epilepticus.

Authors:  Ajith Cherian; Sanjeev V Thomas
Journal:  Ann Indian Acad Neurol       Date:  2009-07       Impact factor: 1.383

Review 10.  [Management of refractory status epilepticus from a neurologic and neuropediatric perspective].

Authors:  B Pohlmann-Eden; U Stephani; I Krägeloh-Mann; B Schmitt; U Brandl; M Holtkamp
Journal:  Nervenarzt       Date:  2007-08       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.